about
Polyionic vaccine adjuvants: another look at aluminum salts and polyelectrolytesAwareness and knowledge about human papillomavirus vaccination and its acceptance in China: a meta-analysis of 58 observational studiesSafety of human papillomavirus vaccines: a reviewGenital human papillomavirus infection among women in Bangladesh: findings from a population-based surveyPost-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience.Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United StatesEfficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial.Early cervical myelitis after human papilloma virus vaccination.Examining a possible association between human papilloma virus (HPV) vaccination and migraine: results of a cohort study in the NetherlandsAssociations Between Exposure to and Expression of Negative Opinions About Human Papillomavirus Vaccines on Social Media: An Observational StudyAdolescent Premature Ovarian Insufficiency Following Human Papillomavirus Vaccination: A Case Series Seen in General PracticeImpact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancerAssessing the need for and acceptability of a free-of-charge postpartum HPV vaccination program.The Yin-Yang arms of vaccines: disease-fighting power versus tissue-destructive inflammation.Human papillomavirus vaccination: where are we now?Strategies for continuous evaluation of the benefit-risk profile of HPV-16/18-AS04-adjuvanted vaccine.Recent progress in vaccination against human papillomavirus-mediated cervical cancer.The safety of human papilloma virus-blockers and the risk of triggering autoimmune diseases.9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV.Incidence rates of Guillain Barré (GBS), chronic fatigue/systemic exertion intolerance disease (CFS/SEID) and postural orthostatic tachycardia syndrome (POTS) prior to introduction of human papilloma virus (HPV) vaccination among adolescent girls inAdverse events following immunization: real causality and myths.Evaluation of optic neuritis following human papillomavirus vaccination.Six-year multi-centre, observational, post-marketing surveillance of the safety of the HPV-16/18 AS04-adjuvanted vaccine in women aged 10-25 years in Korea.Diverse Families' Experiences with HPV Vaccine Information Sources: A Community-Based Participatory Approach.Including males in Canadian human papillomavirus vaccination programs: a policy analysis.British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults 2015.Cervical Cancer Prevention Through HPV Vaccination in Low- and Middle-Income Countries in AsiaHPV vaccine education: enhancing knowledge and attitudes of community counselors and educators.Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon?Knowledge of Saudi female university students regarding cervical cancer and acceptance of the human papilloma virus.Drinking Water to Prevent Postvaccination Presyncope in Adolescents: A Randomized Trial.Human papillomavirus vaccination of adult women and risk of autoimmune and neurological diseases.9-Valent human papillomavirus vaccine: a review of the clinical development program.Association between Human Papilloma Virus (HPV) vaccination and risk of Multiple Sclerosis: A systematic review.HPV prophylactic vaccines: lessons learned from 10 years experience
P2860
Q26852816-1B26379D-AB9A-48CC-8EDC-D30F690376C5Q28066373-C56E2A25-4738-48D8-93F3-733A3A400F7CQ28082119-391F51EC-16FE-48C3-A898-B0A2E66C3728Q30856793-32143FD0-8C2C-4FD7-9CDE-C43809179363Q33163984-AA6FF716-1B4D-444B-8751-0128299D215EQ33166996-4D82A8F4-9B1E-4973-BF98-553230EE5244Q34199560-5F57E712-7F48-4EBF-86E7-1B66619BA5F9Q34376420-528D1079-8AC1-4FE5-849E-CD6FBEAC01A3Q35546272-68ECEF45-2F27-4FFE-99B3-6BCC2D0CECB8Q35922347-715DD28F-3147-45D5-BC68-43256284E517Q35927665-0C681105-42FC-4A3D-8072-5B1F2237632DQ37135163-31EC9BAE-29F0-4293-BD23-EA2432940C5FQ37715865-3DD840C0-6FBC-43B2-B0CD-6ECB7920F54BQ38185741-9968B2C3-0E32-4623-BB4A-3B78E50FEBA7Q38218612-4104E842-D71B-4C6A-AAB7-4DF14E795D77Q38248947-3DC1CBCC-50D2-4416-A1DA-F2722C67633BQ38370782-E193E77A-5A5B-4D2B-882A-F4D520F5F2AEQ38555725-1E5FFE28-166C-4B54-BE8D-9CA9F332C020Q38586257-D3A8E6D9-1308-4C8D-B055-DFECB54B230CQ38655630-09D7882D-AA43-49E4-AD0C-DCD6A3E0279AQ38778111-BFD6EAAF-3C82-40EF-BD17-27965B3F09B6Q38809091-0B914E68-CCE9-4691-A00D-124286D786D5Q38925652-F304AF28-0D36-4433-A472-754F043FF0ECQ39297199-05C44EE9-1083-4A1F-898F-4B960E9FB9CAQ39822006-02981685-FA7F-4D56-AB93-B7193B2C81B0Q40560650-3F0C1DFB-0D1F-4F6D-845F-72158ECB324CQ41929880-78BCD7CE-EFD0-478F-BF6E-F81D9CB610A0Q42260725-D419D8DD-6CB1-47A6-9174-27945189931EQ42361533-6D5EEB69-0831-46F5-878E-2591F9EB4D3EQ42685114-5191DDA7-4A6D-4973-B823-D4826ECA782AQ47829952-1A5FF5F3-A4AE-4CE9-B682-2A9436035A83Q48168601-A6F41530-727A-416A-84AB-DD8E4D15AABCQ49687633-8BCF96AE-06F1-4534-93D3-A10161770DF9Q50542374-0BA146E1-A785-48E9-B441-1F5B4BD8BCD8Q56067928-24D0B8B5-42A4-4EF9-AB99-D1615030765C
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Safety of human papillomavirus vaccines: a review.
@ast
Safety of human papillomavirus vaccines: a review.
@en
type
label
Safety of human papillomavirus vaccines: a review.
@ast
Safety of human papillomavirus vaccines: a review.
@en
prefLabel
Safety of human papillomavirus vaccines: a review.
@ast
Safety of human papillomavirus vaccines: a review.
@en
P2093
P2860
P1433
P1476
Safety of human papillomavirus vaccines: a review.
@en
P2093
Clayton Chiu
Julia M L Brotherton
Kristine K Macartney
Melina Georgousakis
P2860
P2888
P304
P356
10.1007/S40264-013-0039-5
P577
2013-06-01T00:00:00Z
P6179
1023054734